Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics Inc. demonstrated significant progress in its clinical programs, notably achieving sustained visual acuity gains in Phase 1/2a trials for its OpRegen therapy, which supports a positive outlook for its development in treating geographic atrophy. The successful execution of multiple cGMP production runs and the recognition of a $5 million milestone payment from Roche highlight the company's growing credibility and operational capabilities. Additionally, Lineage's revenue surged to $6.6 million in Q4 2025, a substantial increase from $2.9 million in the prior year, primarily driven by collaboration contracts, indicating a strong trajectory for future growth and pipeline expansion.

Bears say

Lineage Cell Therapeutics Inc's financial outlook appears negative due to the inherent risks associated with its clinical-stage status and the uncertainty surrounding the commercial viability of its therapies, including its core programs like OpRegen and OPC1. The company’s reliance on a proprietary manufacturing platform, AlloSCOPE, may not adequately offset the high costs and challenges associated with development and regulatory approval processes. Additionally, potential delays in clinical trials or failure to secure necessary funding could further jeopardize its financial stability and growth prospects.

LCTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, LCTX has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.